NASDAQ:AXGN AxoGen Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AxoGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.12 +0.56 (+4.46 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$12.60Now: $13.12▼$13.8750-Day Range$10.62MA: $11.51▼$12.8852-Week Range$7.16Now: $13.12▼$18.84Volume1.25 million shsAverage Volume453,437 shsMarket Capitalization$525.90 millionP/E RatioN/ADividend YieldN/ABeta0.74 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.38, AxoGen has a forecasted upside of 24.8% from its current price of $13.12.Amount of Analyst CoverageAxoGen has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesAxoGen has received 411 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAxoGen has received 303 “underperform” votes. (Add your “underperform” vote.)Community SentimentAxoGen has received 57.56% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote “Outperform” if you believe AXGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.94% of the stock of AxoGen is held by insiders.Percentage Held by Institutions79.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.90) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -17.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -17.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXGN Previous Symbol CUSIPN/A CIK805928 Webwww.axogeninc.com Phone386-462-6800Debt Debt-to-Equity Ratio0.27 Current Ratio10.00 Quick Ratio9.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$106.71 million Price / Sales4.93 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book3.92Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$-29,140,000.00 Net Margins-28.04% Return on Equity-22.08% Return on Assets-18.11%Miscellaneous EmployeesN/A Outstanding Shares40,084,000Market Cap$525.90 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $13.12 +0.56 (+4.46 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AXGN News and Ratings via Email Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter. AxoGen (NASDAQ:AXGN) Frequently Asked Questions How has AxoGen's stock price been impacted by COVID-19? AxoGen's stock was trading at $10.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXGN stock has increased by 22.6% and is now trading at $13.12. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of AxoGen? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AxoGen. When is AxoGen's next earnings date? AxoGen is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for AxoGen. How were AxoGen's earnings last quarter? AxoGen, Inc (NASDAQ:AXGN) posted its quarterly earnings results on Wednesday, August, 5th. The medical equipment provider reported ($0.20) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.13. The medical equipment provider earned $22.12 million during the quarter, compared to analysts' expectations of $21 million. AxoGen had a negative return on equity of 22.08% and a negative net margin of 28.04%. View AxoGen's earnings history. What guidance has AxoGen issued on next quarter's earnings? AxoGen updated its third quarter 2020 After-Hours earnings guidance on Tuesday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30 million, compared to the consensus revenue estimate of $23.04 million. What price target have analysts set for AXGN? 4 Wall Street analysts have issued 12 month price objectives for AxoGen's shares. Their forecasts range from $13.00 to $21.00. On average, they expect AxoGen's share price to reach $16.38 in the next year. This suggests a possible upside of 24.8% from the stock's current price. View analysts' price targets for AxoGen. Are investors shorting AxoGen? AxoGen saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,190,000 shares, a decline of 15.0% from the August 15th total of 1,400,000 shares. Based on an average daily trading volume, of 388,300 shares, the days-to-cover ratio is currently 3.1 days. Approximately 3.3% of the company's stock are sold short. View AxoGen's Short Interest. Who are some of AxoGen's key competitors? Some companies that are related to AxoGen include InMode (INMD), BioLife Solutions (BLFS), Natus Medical (NTUS), Zynex (ZYXI), Viewray (VRAY), TransMedics Group (TMDX), Semler Scientific (SMLR), Cutera (CUTR), Stereotaxis (STXS), BioSig Technologies (BSGM), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), electroCore (ECOR) and Fc Global Realty (FCRE). View all competitors. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Micron Technology (MU), Xilinx (XLNX), Advanced Micro Devices (AMD), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Intel (INTC), NVIDIA (NVDA), Exelixis (EXEL) and Fossil Group (FOSL). Who are AxoGen's key executives? AxoGen's management team includes the following people: Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)Mr. Peter J. Mariani, Chief Financial Officer (Age 55)Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)Mr. Michael Donovan, VP of Operations (Age 54)Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel. What is AxoGen's stock symbol? AxoGen trades on the NASDAQ under the ticker symbol "AXGN." Who are AxoGen's major shareholders? AxoGen's stock is owned by many different institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (16.78%), Bank of America Corp DE (3.92%), William Blair Investment Management LLC (2.50%), Bank of New York Mellon Corp (1.26%), Granite Investment Partners LLC (1.01%) and Mitsubishi UFJ Trust & Banking Corp (0.90%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan and Quentin S Blackford. View institutional ownership trends for AxoGen. Which institutional investors are selling AxoGen stock? AXGN stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, William Blair Investment Management LLC, Mitsubishi UFJ Trust & Banking Corp, Nuveen Asset Management LLC, Goldman Sachs Group Inc., UBS Group AG, New York State Common Retirement Fund, and Sei Investments Co.. View insider buying and selling activity for AxoGen. Which institutional investors are buying AxoGen stock? AXGN stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, ArrowMark Colorado Holdings LLC, Federated Hermes Inc., Granite Point Capital Management L.P., Assenagon Asset Management S.A., Bank of Montreal Can, Tocqueville Asset Management L.P., and Granite Investment Partners LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej, and Quentin S Blackford. View insider buying and selling activity for AxoGen. How do I buy shares of AxoGen? Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AxoGen's stock price today? One share of AXGN stock can currently be purchased for approximately $13.12. How big of a company is AxoGen? AxoGen has a market capitalization of $525.90 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-29,140,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. What is AxoGen's official website? The official website for AxoGen is www.axogeninc.com. How can I contact AxoGen? AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
